Article: Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
Experimental hematology & oncology
2022 Volume 11, Issue 1, Page(s) 54
Abstract: Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy ... to normal B cells. Using the clinically applicable GPER1-selective small-molecule agonist G-1 (also named ... agonist G-1. ...
Abstract | Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy for treating a variety of human diseases including cancer. Here, we show that GPER1 is significantly upregulated in tumor cells from different cohorts of Waldenström Macroglobulinemia (WM) patients compared to normal B cells. Using the clinically applicable GPER1-selective small-molecule agonist G-1 (also named Tespria), we found that pharmacological activation of GPER1 leads to G2/M cell cycle arrest and apoptosis both in vitro and in vivo in animal models, even in the context of the protective bone marrow milieu. Activation of GPER1 triggered the TP53 pathway, which remains actionable during WM progression. Thus, this study identifies a novel therapeutic target in WM and paves the way for the clinical development of the GPER1 agonist G-1. |
---|---|
Language | English |
Publishing date | 2022-09-12 |
Publishing country | England |
Document type | Letter |
ZDB-ID | 2669066-4 |
ISSN | 2162-3619 |
ISSN | 2162-3619 |
DOI | 10.1186/s40164-022-00305-x |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.